 |
66 Companies | 59 Products |
|
|
59 Products | |
344 Diseases | |
313 Trials |  |
11771 News |  |
| «12...4567891011121314...220221» |
- | Aliqopa (copanlisib) / Bayer
Journal: Pan-PI3K inhibition with copanlisib overcomes Treg- and M2-TAM-mediated immune suppression and promotes anti-tumor immune responses. (Pubmed Central) - Dec 21, 2023
Importantly, in an ICI-sensitive model, combination therapy resulted in complete remission and prevention of tumor recurrence. Thus, the combination of ICIs with PI3K inhibition by intermittently dosed copanlisib represents a promising new strategy to increase sensitivity to ICI therapies and to treat human solid cancers.
- | LY294002 / Eli Lilly
Journal: Leonurine pretreatment protects the heart from myocardial ischemia-reperfusion injury. (Pubmed Central) - Dec 21, 2023
In addition, the upregulation of p-Akt, Bcl-2/Bax induced by SCM-198 treatment were blocked by PI3K inhibitor LY294002, and the total protein level of Akt was not affected by SCM-198 pretreatment. Our experimental results indicated that SCM-198 could have a cardioprotective effect on I/R injury, which confirmed the utility of SCM-198 preconditioning as a strategy to prevent I/R injury.
- Aliqopa (copanlisib) / Bayer
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Window Trial to Evaluate Molecular Response to PI3K Inhibition With Copanlisib in r/r Adult B-cell ALL (clinicaltrials.gov) - Dec 21, 2023
P1, N=3, Terminated, Sponsor: Dorothy Sipkins, MD, PhD
Our experimental results indicated that SCM-198 could have a cardioprotective effect on I/R injury, which confirmed the utility of SCM-198 preconditioning as a strategy to prevent I/R injury. N=10 --> 3 | Trial completion date: May 2024 --> Apr 2023 | Recruiting --> Terminated | Trial primary completion date: May 2024 --> Apr 2023; Sponsor halted clinical development of study drug
- | Aliqopa (copanlisib) / Bayer, Imbruvica (ibrutinib) / AbbVie, J&J
Enrollment closed, Enrollment change: Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL) (clinicaltrials.gov) - Dec 21, 2023
P1/2, N=18, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
N=10 --> 3 | Trial completion date: May 2024 --> Apr 2023 | Recruiting --> Terminated | Trial primary completion date: May 2024 --> Apr 2023; Sponsor halted clinical development of study drug Recruiting --> Active, not recruiting | N=45 --> 18
- | Preclinical, Journal: Recapitulation of anti-aging phenotypes by global overexpression of PTEN in mice. (Pubmed Central) - Dec 20, 2023
These changes in fat, macrophages, liver, muscle, hippocampus, and plasma may be considered "aging rate indicators" in that they seem to be consistently changed across many of the long-lived mouse models and may help to extend lifespan by delaying many forms of late-life illness. Our new findings show that PTENOE mice can be added to the group of long-lived mice that share this multi-tissue suite of biochemical characteristics.
- | Journal: BFGF attenuates aortic valvular interstitial cell calcification by inhibiting endoplasmic reticulum stress-mediated apoptosis. (Pubmed Central) - Dec 20, 2023
In conclusion, BFGF could alleviate the VIC calcification by inhibiting ERS-mediated apoptosis, which is partly regulated by activation of the PI3K/Akt and ERK1/2 signaling pathways. BFGF may provide a potential avenue for CAVD therapy.
- || Monjuvi (tafasitamab-cxix) / Incyte, parsaclisib (INCB50465) / Incyte
Phase classification, Trial completion date, Trial primary completion date, Combination therapy, Pan tumor: topMIND: A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Dec 19, 2023
P1/2, N=54, Active, not recruiting, Sponsor: Incyte Corporation
BFGF may provide a potential avenue for CAVD therapy. Phase classification: P1b/2a --> P1/2 | Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Dec 2024
- | cisplatin / Generic mfg.
Journal: STEAP4 inhibits cisplatin-induced chemotherapy resistance through suppressing PI3K/AKT in hepatocellular carcinoma. (Pubmed Central) - Dec 19, 2023
We also found STEAP4 expression was negatively correlated with PI3K/AKT pathway activity in clinic specimens. In summary, our findings suggested STEAP4 inhibited cisplatin resistance through suppressing PI3K/AKT pathway activity, providing a target for HCC therapy.
- | Journal, IO biomarker: Robinin inhibits pancreatic cancer cell proliferation, EMT and inflammation via regulating TLR2-PI3k-AKT signaling pathway. (Pubmed Central) - Dec 19, 2023
Robinin exerts anti-tumor effect perhaps via downregulating inflammation and EMT in pancreatic cancer cell through inhibiting TLR2-PI3k-AKT signaling pathway. Robinin may be a novel agent in adjuvant therapy of pancreatic cancer.
- | LY294002 / Eli Lilly
Journal: LncRNA MALAT1 Expression Regulates Breast Cancer Progression via PI3K/AKT/mTOR Pathway Modulation. (Pubmed Central) - Dec 19, 2023
The study also investigated the cross-talk of lncRNA MALAT1 and PI3K pathway genes by inhibiting it with PI3K inhibitor (LY294002) in MDA-MB-231 cell line...Moreover, the study proposes a mechanism of action of MALAT1, demonstrating that its inhibition can reduce the expression of the PI3K/AKT/mTOR axis. These findings emphasize the potential significance of targeting MALAT1 as a therapeutic strategy for breast cancer, and further exploration of this interaction is warranted to gain deeper insight into the molecular mechanism of this lncRNA.
- || Review, Journal: A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action. (Pubmed Central) - Dec 18, 2023
In conclusion, EA exhibits anticancer activity through various molecular mechanisms that influence key cellular processes like apoptosis, cell cycle, angiogenesis, and metastasis in BC. However, further researches are essential to fully elucidate its molecular targets and implications for clinical applications.
- | Piqray (alpelisib) / Novartis
Retrospective data, Journal, Metastases: Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer. (Pubmed Central) - Dec 18, 2023
Elevated baseline HbA1c is associated with alpelisib-induced hyperglycemia and requiring dose modification. Optimization of glycemic status before alpelisib initiation should become routine practice.
- | VS-5584 / Verastem
Preclinical, Journal: The lncRNA expression profile signature of leukemia stem cells is altered upon PI3K/mTOR inhibition: an in vitro and in silico study. (Pubmed Central) - Dec 18, 2023
We suppressed PI3K/Akt/mTOR signaling in LSC and HSC cell-lines by specific PI3K/mTOR dual-inhibitor (VS-5584) and confirmed the inhibition by antibody-array...SRA was predicted to interact with CREB1, RARA, and PPARA. The possible DELs' targets were predicted to form six ontological groups, be highly enriched for phosphoprotein, and be involved in "PPAR signaling pathway" and "ChREBP regulation by carbohydrates and cAMP." These results will help to elucidate the roles of lncRNAs in the mechanisms that provide selective advantages to leukemia stem cells.
- | Journal: ?-1,3-d-glucan particles-based "nest" protected co-loaded Rhein and Emodin regulates microbiota and intestinal immunity for ulcerative colitis treatment. (Pubmed Central) - Dec 17, 2023
Even more crucially, the oral delivery and drug combination methods significantly enhanced the regulatory effects of HA-RH/EMO NYPs on gut microbiota and the Th17/Treg balance. Overall, this research marks the first use of YPs to encapsulate two components, RH and EMO, presenting a promising therapeutic strategy for UC.
- | LY294002 / Eli Lilly
Journal, IO biomarker: The Role of Bcl-2 and Beclin-1 Complex in "Switching" between Apoptosis and Autophagy in Human Glioma Cells upon LY294002 and Sorafenib Treatment. (Pubmed Central) - Dec 17, 2023
Overall, this research marks the first use of YPs to encapsulate two components, RH and EMO, presenting a promising therapeutic strategy for UC. "Switching" between apoptosis and autophagy using PI3K and Raf inhibitors with Bcl-2:beclin-1 complex formation opens new therapeutic perspectives against gliomas.
- | Journal: New Dipyrroloquinones from a Plant-Derived Endophytic Fungus Talaromyces sp. (Pubmed Central) - Dec 17, 2023
"Switching" between apoptosis and autophagy using PI3K and Raf inhibitors with Bcl-2:beclin-1 complex formation opens new therapeutic perspectives against gliomas. As a result, 1-3 inhibited the LPS-stimulated NO production in macrophage RAW264.7 cells, with IC values of 20.3, 30.7, and 20.6
- | Journal: Melatonin Inhibits Testosterone Synthesis in Rooster Leydig Cells by Targeting CXCL14 through miR-7481-3p. (Pubmed Central) - Dec 17, 2023
Interference with CXCL14 significantly inhibited the phosphorylation level of PI3K and AKT, and the inhibited PI3K/AKT signal pathway could reverse the inhibitory effect of CXCL14 on testosterone synthesis and the expression of StAR, CYP11A1 and 3?-HSD in rooster Leydig cells. Our results indicated that melatonin inhibits testosterone synthesis by targeting miR-7481-3p/CXCL14 and inhibiting the PI3K/AKT pathway.
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience
Journal, PARP Biomarker: Chidamide inhibits proliferation and promotes apoptosis of esophageal squamous cell carcinoma cells by inhibiting the PI3K/Akt and ERK1/2 pathways and increasing DNA damage (Pubmed Central) - Dec 17, 2023
Chidamide inhibits proliferation, induces apoptosis and blocks cell cycle of ESCC cells possibly by inhibiting the PI3K/Akt and ERK1/2 pathways and increasing DNA damage. Chidamide also inhibits subcutaneous tumorigenesis of ESCC cells in mice by inhibiting tumor cell proliferation and angiogenesis.
- || Herceptin (trastuzumab) / Roche, Tagrisso (osimertinib) / AstraZeneca, Lumakras (sotorasib) / Amgen
Review, Journal, Tumor mutational burden: The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review. (Pubmed Central) - Dec 17, 2023
To our knowledge, this is the most comprehensive review to date of the impact of genomic context on outcomes with targeted therapy. It represents a valuable resource informing progress towards contextualised precision medicine.
- | Journal: Evaluation of the anti-inflammatory effects of PI3K?/? inhibitors for treating acute lung injury. (Pubmed Central) - Dec 17, 2023
inhibition could be ideal targets to treat respiratory inflammatory diseases by reducing the inflammatory response. The findings of the current study provide a new basis for utilizing PI3K inhibitors to treat acute respiratory inflammatory diseases.
- | omipalisib (GSK2126458) / GSK
Journal: Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis. (Pubmed Central) - Dec 17, 2023
Gedatolisib and dactolisib, another two PI3K/mTOR inhibitors, exerted similar effects without affecting mitochondria biogenesis. These results highlight the multifaceted anti-leukemic effect of omipalisib, revealing its potential as a novel therapeutic agent in AML treatment.
- | buparlisib (AN2025) / Novartis, Adlai Nortye
Journal: Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. (Pubmed Central) - Dec 17, 2023
Reducing insulin feedback improves the efficacy of PI3K inhibition in GBM in mice, and hyperglycemia worsens progression-free survival in patients with GBM treated with PI3K inhibition. These findings indicate that hyperglycemia is a critical resistance mechanism associated with PI3K inhibition in GBM and that anti-hyperglycemic therapy may enhance PI3K inhibitor efficacy in GBM patients.
- | LY294002 / Eli Lilly
Journal: The CXCL10/CXCR3 axis regulates Th1 cell differentiation and migration in experimental autoimmune prostatitis through the PI3K/AKT pathway. (Pubmed Central) - Dec 14, 2023
These findings indicate that hyperglycemia is a critical resistance mechanism associated with PI3K inhibition in GBM and that anti-hyperglycemic therapy may enhance PI3K inhibitor efficacy in GBM patients. Our investigations indicate that the CXCL10/CXCR3 axis regulates Th1 cell differentiation and migration in EAP through the PI3K/AKT pathway, which provides a new perspective on the immunological mechanisms of CP/CPPS.
- | Journal, IO biomarker: Hugan Buzure Induces Autophagy and Apoptosis in Hepatocellular Carcinoma by Inhibiting PI3K/Akt/mTOR Signaling Pathway. (Pubmed Central) - Dec 14, 2023
In conclusion, HBR induced autophagy and apoptosis through PI3K/Akt/mTOR signaling pathway, leading to HCC cell death. This research preliminarily suggested the potential role of HBR in the treatment of HCC.
- | Journal: The quantitative pyrrole protection of l-phenylalanine/l-phenylalaninol in aqueous media and rationally updating the mechanisms of the Clauson-Kaas reaction through DFT study. (Pubmed Central) - Dec 13, 2023
In addition to the relationally neighbouring intramolecular catalytic effect from the amino acid, the crucial "H-bridge" interplay of water, along with the suggestion of a biomimetic route features similar to the N-glycosylation of carbohydrates, probably indicates the totally different reaction courses. The auto-catalysis ability of l-phenylalanine was also extensively investigated by comparisons on the details relating to l-phenylalaninol.
- | LY294002 / Eli Lilly
Preclinical, Journal: Astragaloside IV promotes cerebral angiogenesis and neurological recovery after focal ischemic stroke in mice via activating PI3K/Akt/mTOR signaling pathway. (Pubmed Central) - Dec 13, 2023
Finally, AS-IV increased the expression of vascular endothelial growth factor (VEGF) through activating the PI3K/AKT/mTOR signaling pathway in the process of promoting angiogenesis. These results suggested that AS-IV may promote angiogenesis after ischemic stroke through increasing the expression of VEGF via PI3K/Akt/mTOR pathway, which unveils novel therapeutic effects of AS-IV and suggests promising application of AS-IV in ischemic stroke.
- | Epidaza (chidamide) / Chipscreen, Meiji Seika, Eisai, HUYA Bioscience, parsaclisib (INCB50465) / Incyte
Enrollment open: PI3K? Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma (clinicaltrials.gov) - Dec 12, 2023
P1/2, N=28, Recruiting, Sponsor: Henan Cancer Hospital
These results suggested that AS-IV may promote angiogenesis after ischemic stroke through increasing the expression of VEGF via PI3K/Akt/mTOR pathway, which unveils novel therapeutic effects of AS-IV and suggests promising application of AS-IV in ischemic stroke. Not yet recruiting --> Recruiting
- Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Phase I Study of Duvelisib Study for Cytokine Release Syndrome Prophylaxis in Patients Receiving Chimeric Antigen Receptor T Cell Treatment for Non-Hodgkin Lymphoma () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_788;
P1
In 17 evaluated pts, CAR T-cell expansion by flow cytometry was robust at all dose levels, consistent with prior reports (Figure 1B). Preliminary data from this phase I study suggests that duvelisib as CRS prophylaxis after SoC CAR T-cell therapy is safe and tolerable and may prevent grade 3-4 CRS and delay the onset of CRS.
- | Preclinical, Journal: Fabrication, in-silico, in-vitro, and in-vivo characterization of transferrin-targeted micelles containing cisplatin and gadolinium for improved theranostic applications in lung cancer therapy. (Pubmed Central) - Dec 11, 2023
The biochemical studies have proved the biocompatibility of developed micelles formulations by showing no sign of toxicity in the lungs. The developed micelles have great potential to be utilized in treating and diagnosing a wide variety of cancers.
- | Biomarker, Journal, Tumor microenvironment, Tumor cell: Neuromedin U regulates the anti-tumor activity of CD8 T cells and glycolysis of tumor cells in the tumor microenvironment of pancreatic ductal adenocarcinoma in an NMUR1-dependent manner. (Pubmed Central) - Dec 10, 2023
The developed micelles have great potential to be utilized in treating and diagnosing a wide variety of cancers. In
- | Piqray (alpelisib) / Novartis
Journal: Alpelisib decreases nevocytes of congenital melanocytic nevi. (Pubmed Central) - Dec 10, 2023
Alpelisib is an approved drug with an adequate safety profile used in another mosaicism affecting PI3K (PROS). Further studies are needed to evaluate its efficacy in treating CMN and potentially, their complications, either with local or systemic administration, alone or in combination.
- | Journal: Red ginseng polysaccharide promotes ferroptosis in gastric cancer cells by inhibiting PI3K/Akt pathway through down-regulation of AQP3. (Pubmed Central) - Dec 9, 2023
Confirmatory in vivo experiments showed that RGP could reduce the growth of implanted tumor, with increased RGP concentration resulting in greater tumor inhibitory effects. RGP might have therapeutic potential against GC, effectively inhibiting the proliferation and viability of AGS cells.
- | sirolimus / Generic mfg.
Journal: FilGAP regulates tumor growth in Glioma through the regulation of mTORC1 and mTORC2. (Pubmed Central) - Dec 9, 2023
The mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase that forms the two different protein complexes, known as mTORC1 and mTORC2...Finally, we showed that depletion of FilGAP in KINGS-1 and U-87MG cells significantly reduced spheroid growth. These results suggest that FilGAP may contribute to tumor growth in glioma by regulating mTORC1/2 activities.
- | Journal: The dual HDAC and PI3K inhibitor, CUDC?907, inhibits tumor growth and stem?like properties by suppressing PTX3 in neuroblastoma. (Pubmed Central) - Dec 8, 2023
IHC revealed that the high expression of HDAC1, 2, 3 and CD44 was associated with a poor prognosis of patients with NB. On the whole, these findings indicate that CUDC?907 may be developed into a possible therapeutic approach for patients with NB.
- | Preclinical, Journal: MiR-182 promotes apoptosis of neural cells in cerebral infarction rats by PI3K/AKT signaling pathway. (Pubmed Central) - Dec 8, 2023
Overexpression of miR-182 significantly reduced the protein expression levels of phosphatidylinositol 3-hydroxy kinase (PI3K) and p-AKT. MiR-182 induces apoptosis of neural cells through inhibiting the PI3K/AKT signaling pathway, which plays an important regulatory role in the apoptosis of neural cells in cerebral infarction rats.
- | LY294002 / Eli Lilly
Journal: Emodin exhibits anti-acne potential by inhibiting cell growth, lipogenesis, and inflammation in human SZ95 sebocytes. (Pubmed Central) - Dec 7, 2023
In addition, emodin could decrease the secretion of pro-inflammatory cytokines IL-6 and IL-8, and suppress the expression of NLRP3, capase-1, IL-1?, and IL-18 in SZ95 sebocytes exposed to Cutibacterium acnes. Overall, our study provides preliminary evidence supporting the anti-growth, anti-lipogenic and anti-inflammatory properties of emodin, indicating the potential therapeutic application of emodin for acne treatment.
- | Journal: Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms. (Pubmed Central) - Dec 7, 2023
Finally, ?-KG incubation significantly decreased proinflammatory cytokine secretion from MPN CD14+ monocytes. Our results reveal a previously unrecognized metabolic disorder in conjunction with aberrant PI3K/AKT/mTOR signaling, contributing to platelet hyperreactivity in MPN patients.
- | Journal: Depleting ANTXR1 suppresses glioma growth via deactivating PI3K/AKT pathway. (Pubmed Central) - Dec 7, 2023
ANTXR1 could play an indispensable role in glioma tumorigenesis via activating PI3K/AKT-mediated cell growth. Our study provides a theoretical basis for targeting ANTXR1 as a molecular target in glioma clinical therapeutics.
- | LY294002 / Eli Lilly
Preclinical, Journal: Tsantan Sumtang, a traditional Tibetan medicine, protects pulmonary vascular endothelial function of hypoxia-induced pulmonary hypertension rats through AKT/eNOS signaling pathway. (Pubmed Central) - Dec 6, 2023
TS restored pulmonary arterial endothelial function in HPH rats. The bioactive fraction 17 was screened, which protected hypoxia-injured PAECs via upregulating AKT/eNOS signaling.
- || Review, Journal: Emerging treatment approaches for triple-negative breast cancer. (Pubmed Central) - Dec 5, 2023
These advancements present a promising frontier for tailored interventions with the potential to significantly improve outcomes for TNBC patients. Interestingly, while TNBC poses a complex challenge, it also serves as a paradigm and an opportunity for translational research and innovative therapies in the field of oncology.
- | Journal: Flow induces common and specific transcriptional changes in renal tubular epithelial cells involving the PI3K pathway. (Pubmed Central) - Dec 5, 2023
This suggests that the PI3K pathway is a critical mediator in flow-dependent cellular processes and gene expression, potentially influencing renal development and tissue remodeling. Finally, we derived a cross-cell-line summary of common as well as segment-specific transcriptomic effects, thus providing insights into the molecular mechanisms underlying flow sensing in the nephron tubule.
- | cisplatin / Generic mfg.
Journal: Catalytic Tunable Black Phosphorus/Ceria Nanozyme: A Versatile Oxidation Cycle Accelerator for Alleviating Cisplatin-Induced Acute Kidney Injury. (Pubmed Central) - Dec 5, 2023
However, in the acidic environment of cancers, the presence of H+ inhibited the conversion of Ce4+ to Ce3+, which in turn disrupted the oxidative cycle, resulting in the loss of ROS scavenging ability and ensuring the antitumor effect of DDP. Conclusively, the nanozymes offer an excellent antioxidant for alleviating cisplatin-induced AKI and extensively using in other ROS-based injuries.
- | Piqray (alpelisib) / Novartis
Trial completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Dec 5, 2023
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Conclusively, the nanozymes offer an excellent antioxidant for alleviating cisplatin-induced AKI and extensively using in other ROS-based injuries. Trial completion date: Oct 2023 --> May 2024
- | Itari (linperlisib) / Shanghai YingLi Pharma
Enrollment closed: Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia (clinicaltrials.gov) - Dec 5, 2023
P1, N=8, Active, not recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Trial completion date: Oct 2023 --> May 2024 Recruiting --> Active, not recruiting
- | Journal: Ferroptosis-enhanced chemotherapy for triple-negative breast cancer with magnetic composite nanoparticles. (Pubmed Central) - Dec 4, 2023
Recruiting --> Active, not recruiting Furthermore, transcriptomic analyses demonstrated that FeO-PASP-DOX-induced apoptosis could be enhanced by FeO-PGA-DHA-induced ferroptosis and FeO-PGA-DHA
- | Journal: FGF10 attenuates allergic airway inflammation in asthma by inhibiting PI3K/AKT/NF-?B pathway. (Pubmed Central) - Dec 4, 2023
Furthermore, transcriptomic analyses demonstrated that FeO-PASP-DOX-induced apoptosis could be enhanced by FeO-PGA-DHA-induced ferroptosis and FeO-PGA-DHA Asthma airway inflammation could be attenuated by Fgf10 in this study, suggesting that it could be a potential therapeutic target.
- | Journal: Blue light photobiomodulation induced apoptosis by increasing ROS level and regulating SOCS3 and PTEN/PI3K/AKT pathway in osteosarcoma cells. (Pubmed Central) - Dec 4, 2023
Meanwhile, SOCS3 is a major inducible anti-tumor molecule, we also found that blue light LED substantially promoted its expression. Thus, this study proposed that bule light PBM may be a hopeful therapeutic approach in OS clinical treatment in the future.
- | Preclinical, Journal: Explore novel molecular mechanisms of FNDC5 in ischemia-reperfusion (I/R) injury by analyzing transcriptome changes in mouse model of skeletal muscle I/R injury with FNDC5 knockout. (Pubmed Central) - Dec 4, 2023
This study demonstrates that FNDC5 deletion exacerbates skeletal muscle I/R injury, potentially involving the upregulation of Col6a2, Enpep, and Mmp11. Additionally, the findings suggest the involvement of the PI3K-Akt pathway in FNDC5 deletion-mediated skeletal muscle I/R injury, providing novel insights into the molecular mechanisms underlying FNDC5's role in this pathological process.
- | Piqray (alpelisib) / Novartis
Journal: Mutant PIK3CA is a targetable driver alteration in histiocytic neoplasms. (Pubmed Central) - Dec 4, 2023
Alpelisib demonstrated a tolerable safety profile at a dose of 750mg/week and clinical and metabolic complete remission in a PIK3CA-mutated LCH patient. These data demonstrate PIK3CA as a targetable non-canonical driver of LCH and underscore the importance of mutational analysis-based personalized treatment in histiocytic neoplasms.
- | Mekinist (trametinib) / Novartis, BeiGene, Aliqopa (copanlisib) / Bayer
Preclinical, Journal, Tumor cell: Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. (Pubmed Central) - Dec 4, 2023
These data demonstrate PIK3CA as a targetable non-canonical driver of LCH and underscore the importance of mutational analysis-based personalized treatment in histiocytic neoplasms. Abrogation of lactate-mediated cross-talk between cancer cells and TAM results in durable ADT-independent tumor control in PTEN/p53-deficient AVPC, and warrants further investigation in clinical trials.